Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances

Tango Therapeutics, Inc.

Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).
Cash $336.9M at Dec 31, 2023; plus $41.7M from Jan 2024 ATM; runway into late 2026.
Four phase 1/2 trials ongoing; TNG908 clinical data expected 2024; first patient dosed for TNG348.
FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas.
Appointed Chief Regulatory Officer, Chief Development Operations Officer, Chief Legal Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tango Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 18, 2024, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter and year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-032513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.